interferoninduc
antivir
factor
block
cellular
releas
variou
envelop
virus
previous
report
human
coronaviru
infect
allevi
tether
virion
downregul
cell
surfac
suggest
coronavirus
capabl
encod
factor
report
new
find
sever
acut
respiratori
syndrom
coronaviru
sarscov
spike
glycoprotein
similar
vpu
capabl
antagon
tether
sarscov
viruslik
particl
via
downregul
howev
unlik
vpu
downmodul
mean
proteasom
lysosom
degrad
pathway
downregul
appar
mediat
sarscov
lysosom
degrad
pathway
found
sarscov
coloc
reduc
cell
surfac
suggest
associ
sarscov
target
lysosom
degrad
pathway
accord
one
recent
report
sarscov
antagon
interf
glycosyl
data
provid
support
propos
sarscov
envelop
virus
capabl
evolv
supplementari
factor
manner
requir
viru
replic
experi
requir
determin
whether
restrict
authent
sarscov
virion
allevi
sarscov
spike
protein
k
e
w
r
coronaviru
human
immunodefici
viru
immun
respons
innat
immun
sar
coronaviru
viru
classif
bone
marrow
stromal
antigen
also
design
tetherin
type
ii
integr
membran
protein
contain
cytoplasm
ntermin
region
follow
span
transmembran
domain
carboxytermin
glycosylphosphatidylinositol
gpi
anchor
interferoninduc
gene
function
innat
defens
system
viru
infect
describ
host
restrict
factor
capabl
imped
releas
sever
type
envelop
virus
includ
retrovirus
filovirus
arenavirus
influenza
sendai
viru
one
research
team
propos
inhibit
viru
releas
tether
nascent
virion
cell
surfac
via
ntermin
transmembran
domain
ctermin
gpi
anchor
envelop
virus
bud
directli
cell
surfac
small
number
envelop
virus
eg
herpesvirus
subject
restrict
even
though
final
envelop
entail
membran
tgn
andor
endosom
compart
egress
via
exocytosi
previou
studi
report
human
coronaviru
whose
assembl
bud
occur
ergolgi
intermedi
compart
whose
virion
releas
via
vesicl
exocytosi
also
subject
inhibit
result
electron
microscopi
analys
indic
presenc
virion
cell
surfac
membran
intracellular
vesicl
tend
cluster
suggest
tether
bud
virion
vesicl
membran
remain
cell
surfac
plasma
membran
exocytosi
describ
moder
restrict
releas
hepat
c
viru
whose
assembl
take
place
er
whose
releas
cell
via
secretori
pathway
occur
manner
similar
coronavirus
combin
data
support
assumpt
envelop
viru
bud
releas
occur
plasma
membran
intracellular
compart
subject
block
compon
innat
immun
respons
form
restrict
envelop
virion
releas
mani
virus
evolv
specif
antagonist
counteract
antivir
activ
vpu
env
simian
immunodefici
viru
siv
nef
env
ebola
sendai
viru
gp
kaposi
sarcomaassoci
herpesviru
influenza
viru
neuraminidas
capabl
antagon
sinc
viral
factor
viral
envelop
glycoprotein
specul
sarscov
spike
glycoprotein
may
possess
properti
counteract
block
viru
releas
work
built
part
earlier
find
anoth
research
team
accessori
protein
encod
sarscov
inhibit
tether
virion
also
found
sarscov
spike
protein
capabl
downmodul
thu
mitig
restrict
viruslik
particl
vlp
releas
suggest
sarscov
envelop
virus
capabl
evolv
addit
factor
mammalian
express
vector
encod
sarscov
n
e
provid
g
j
nabel
dimerizationdefect
mutant
gift
klau
strebel
plasmid
ptrehn
kindli
provid
volker
thiel
serv
templat
gener
pcr
product
contain
nucldocapsid
code
sequenc
use
forward
primer
revers
supplement
fetal
calf
serum
invitrogen
confluent
cell
trypsin
seed
onto
cm
dish
plate
hour
transfect
construct
cell
transfect
plasmid
dna
calcium
phosphat
precipit
method
chloroquin
ad
enhanc
transfect
effici
unless
otherwis
indic
plasmid
use
cotransfect
hela
transfect
plasmid
dna
mix
gencarri
epoch
biolab
ratio
transfect
procedur
perform
accord
manufactur
protocol
human
coronaviru
propag
hela
cell
describ
previous
detect
mous
monoclon
antibodi
use
probe
human
mous
antiserum
abcam
rabbit
antiserum
vpu
detect
rabbit
antiserum
secondari
antibodi
sheep
antimous
donkey
antirabbit
horseradish
peroxidas
hrp
conjug
antibodi
invitrogen
also
use
hela
cell
constitut
express
assess
impact
endogen
vlp
yield
found
form
stabl
cysteinelink
dimer
block
dimer
replac
cystein
alanin
ectodomain
turn
block
inhibit
releas
suggest
dimer
requir
virion
releas
block
test
whether
dimer
also
requir
n
panel
b
panel
c
plu
wildtyp
mutant
express
vector
contain
alanin
substitut
three
cystein
residu
ectodomain
cell
supernat
harvest
subject
western
immunoblot
hour
posttransfect
bone
marrow
stromal
antigen
vlp
viruslik
particl
suggest
dimer
requir
inhibit
coronaviru
vlp
releas
state
sever
viral
membran
glycoprotein
siv
env
well
ebola
sendai
viru
gp
protein
exert
counteract
effect
therefor
attempt
identifi
activ
associ
sarscov
spike
protein
sinc
known
restrict
releas
absenc
vpu
perform
test
determin
whether
sarscov
counteract
therefor
support
releas
shown
upper
panel
figur
lane
vs
lane
inhibitori
effect
virion
releas
decreas
presenc
either
sarscov
vpu
step
reduc
express
figur
middl
panel
lane
suggest
sarscov
capabl
promot
releas
viru
particl
cell
via
downregul
addit
experi
confirm
sarscov
like
vpu
capabl
reduc
express
dosedepend
manner
figur
c
combin
data
suggest
sarscov
may
counteract
restrict
vlp
releas
bind
vpu
move
toward
lysosomaland
proteasomaldegrad
pathway
next
task
examin
whether
sarscov
mediat
degrad
via
similar
pathway
transfect
treat
either
proteasom
inhibitor
ammonium
chlorid
nh
cl
lysosom
inhibitor
found
downregul
mediat
sarscov
significantli
affect
proteasom
function
inhibit
notic
reduc
follow
lysosom
function
inhibit
figur
lane
consist
previou
report
observ
proteasom
lysosom
function
inhibit
result
markedli
reduc
vpumedi
downregul
figur
lane
suggest
downregul
mediat
sarscov
larg
occur
via
lysosom
degrad
pathway
sinc
larg
local
cell
surfac
tether
virion
prevent
releas
test
whether
sarscov
antagon
via
surfac
downregul
cell
cotransfect
sarscov
express
vector
observ
coloc
perinuclear
area
signal
bare
detect
cell
surfac
instead
larg
local
perinuclear
area
regardless
whether
coexpress
figur
consist
previou
report
unlik
helaendogen
local
cell
surfac
well
perinuclear
area
exogen
predominantli
local
perinuclear
area
littl
distribut
cell
surfac
nevertheless
flow
cytometri
quantif
suggest
cell
surfac
express
notic
reduc
cell
follow
sarscov
coexpress
figur
case
hela
cell
constitut
express
found
sarscov
coloc
plasma
membran
figur
green
fluoresc
intens
hela
cell
surfac
decreas
slightli
follow
sarscov
coexpress
suggest
capac
sarscov
counteract
inhibit
virion
releas
due
part
cell
surfac
downmodul
capabl
inhibit
sarscov
vlp
releas
figur
sinc
inhibit
releas
via
virion
tether
cell
surfac
well
document
use
vpudefici
virusproduc
vector
control
experi
shown
figur
coronaviru
vlp
similar
tether
cell
surfac
inhibit
sarscov
vlp
releas
dimerizationdepend
manner
similar
figur
manner
vpu
sarscov
facilit
releas
via
downregul
figur
determin
vpu
downmodul
via
proteasom
lysosom
degrad
pathway
predomin
lysosom
pathway
mediat
sarscov
figur
confoc
microscopi
observ
suggest
sarscov
coloc
hela
cell
surfac
figur
sarscov
like
bind
serv
target
lysosom
degrad
vpu
capabl
trap
intracellularli
prevent
recycl
back
plasma
membran
whether
sarscov
similarli
counteract
requir
investig
transmembran
protein
sarscov
shown
counteract
tether
interf
glycosyl
addit
likelihood
restrict
f
g
u
r
e
sarscov
glycoprotein
coloc
cell
panel
cotransfect
srascov
express
vector
hela
cell
panel
b
transfect
sarscov
express
vector
hour
posttransfect
cell
probe
antibodi
cell
membran
permeabil
sarscov
probe
anti
polyclon
antiserum
rhodamineconjug
fitcconjug
antirabbit
antimous
antibodi
serv
secondari
antibodi
c
sarscov
coexpress
reduc
cell
surfac
express
cell
transfect
alon
middl
panel
togeth
sarscov
express
vector
bottom
panel
hour
posttransfect
cell
fix
probe
rabbit
antibodi
permeabil
cell
membran
follow
secondari
fitcconjug
antirabbit
antibodi
cell
analyz
flow
cytometri
bone
marrow
stromal
antigen
sarscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
virion
releas
mitig
sarscov
possibl
number
envelop
virus
develop
supplementari
factor
timenot
addit
vpu
nef
capabl
overcom
restrict
viru
releas
certain
condit
siv
nef
env
capabl
antagon
influenza
neuraminidas
protein
possess
capabl
research
suggest
influenza
andor
ebola
vlp
releas
virion
releas
inhibit
due
biosafeti
requir
current
unabl
perform
test
determin
whether
sarscov
capabl
overcom
restrict
sarscov
virion
releas
